Literature DB >> 23066312

Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B.

Hui Zhang1, Qing-Ya Li, Zhi-Zhong Guo, Yan Guan, Jia Du, Yi-Yu Lu, Yi-Yang Hu, Ping Liu, Shuang Huang, Shi-Bing Su.   

Abstract

AIM: To investigate whether circulating microRNAs (miRNAs) can serve as molecular markers to predict liver injury resulted from chronic hepatitis B (CHB).
METHODS: The profiles of serum miRNA expression were first generated with serum samples collected from 10 patients with CHB and 10 healthy donors (Ctrls) by microarray analysis. The levels of several miRNAs were further quantitated by real-time reverse transcription polymerase chain reaction with serum samples from another 24 CHB patients and 24 Ctrls. Serum samples of 20 patients with nonalcohlic steatohepatitis (NASH) were also included for comparison. The comparison in the levels of miRNAs between groups (CHB, NASH and Ctrl) was analyzed with Mann-Whitney U-test. The correlation between miRNAs and clinical pathoparameters was analyzed using Spearman correlation analysis or canonical correlation analysis. The receiver-operator characteristic (ROC) curves were also generated to determine the specificity and sensitivity of each individual miRNA in distinguishing patients with CHB from Ctrls.
RESULTS: miRNA profile analysis showed that 34 miRNAs were differentially expressed between CHB and Ctrl subjects, in which 12 were up-regulated and 22 down-regulated in CHB subject (fold change > 2.0 and P < 0.01). The median levels of miR-122, -572, -575 and -638 were significantly higher (P < 1.00 × 10(-5)) while miR-744 significantly lower (P < 1.00 × 10(-6)) in CHB compared with the Ctrl. The levels of miR-122, -572 and -638 were also higher (P < 1.00 × 10(-3)) while the level of miR-744 lower in CHB (P < 0.05) than in NASH, although the difference between them was not as significant as that between CHB and Ctrl. ROC curve analysis revealed that the levels of miR-122, -572, -575, -638 and -744 in serum were sensitive and specific enough to distinguish CHB, NASH and Ctrl. Multivariate analysis further showed that the levels of these miRNAs were correlated with the liver function parameters. Most significantly, it was the scatter plot of principal component with the levels of these miRNAs, but not the parameters of liver function, which clearly distinguished CHB, NASH and Ctrl subjects.
CONCLUSION: Serum levels of miR-122, -572, -575, -638 and -744 are deregulated in patients with CHB or NASH. The levels of these miRNAs may serve as potential biomarkers for liver injury caused by CHB and NASH.

Entities:  

Keywords:  Chronic hepatitis B; Liver injury; Nonalcohlic steatohepatitis; Serum microRNAs

Mesh:

Substances:

Year:  2012        PMID: 23066312      PMCID: PMC3468850          DOI: 10.3748/wjg.v18.i37.5188

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Serum miR-146a and miR-223 as potential new biomarkers for sepsis.

Authors:  Jia-feng Wang; Man-li Yu; Guang Yu; Jin-jun Bian; Xiao-ming Deng; Xiao-jian Wan; Ke-ming Zhu
Journal:  Biochem Biophys Res Commun       Date:  2010-02-24       Impact factor: 3.575

2.  A translational study of circulating cell-free microRNA-1 in acute myocardial infarction.

Authors:  Yunhui Cheng; Ning Tan; Jian Yang; Xiaojun Liu; Xiaopei Cao; Pengcheng He; Xiaoli Dong; Shanshan Qin; Chunxiang Zhang
Journal:  Clin Sci (Lond)       Date:  2010-04-20       Impact factor: 6.124

3.  Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection.

Authors:  Alma Zernecke; Kiril Bidzhekov; Heidi Noels; Erdenechimeg Shagdarsuren; Lin Gan; Bernd Denecke; Mihail Hristov; Thomas Köppel; Maliheh Nazari Jahantigh; Esther Lutgens; Shusheng Wang; Eric N Olson; Andreas Schober; Christian Weber
Journal:  Sci Signal       Date:  2009-12-08       Impact factor: 8.192

Review 4.  Pathogenesis of hepatitis B virus infection.

Authors:  F V Chisari; M Isogawa; S F Wieland
Journal:  Pathol Biol (Paris)       Date:  2010-02-08

5.  Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases.

Authors:  Yi Zhang; Yin Jia; Ruiying Zheng; Yingjun Guo; Yue Wang; Hui Guo; Mingyu Fei; Shuhan Sun
Journal:  Clin Chem       Date:  2010-10-07       Impact factor: 8.327

6.  Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans.

Authors:  Guo-Kun Wang; Jia-Qi Zhu; Jun-Tao Zhang; Qing Li; Yue Li; Jia He; Yong-Wen Qin; Qing Jing
Journal:  Eur Heart J       Date:  2010-02-16       Impact factor: 29.983

7.  MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer.

Authors:  Kah Hoong Chang; Pieter Mestdagh; Jo Vandesompele; Michael J Kerin; Nicola Miller
Journal:  BMC Cancer       Date:  2010-04-29       Impact factor: 4.430

8.  Altered microRNA expression following traumatic spinal cord injury.

Authors:  Nai-Kui Liu; Xiao-Fei Wang; Qing-Bo Lu; Xiao-Ming Xu
Journal:  Exp Neurol       Date:  2009-07-01       Impact factor: 5.330

9.  Apoptosis and cytokines in non-alcoholic steatohepatitis.

Authors:  Wing-Kin Syn; Steve S Choi; Anna Mae Diehl
Journal:  Clin Liver Dis       Date:  2009-11       Impact factor: 6.126

10.  Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies.

Authors:  Junhao Gui; Yaping Tian; Xinyu Wen; Wenhui Zhang; Pengjun Zhang; Jing Gao; Wei Run; Liyuan Tian; Xingwang Jia; Yanhong Gao
Journal:  Clin Sci (Lond)       Date:  2011-03       Impact factor: 6.124

View more
  30 in total

1.  MicroRNAs in Liver Disease: Bench to Bedside.

Authors:  Nihar Shah; James E Nelson; Kris V Kowdley
Journal:  J Clin Exp Hepatol       Date:  2013-09-17

2.  MicroRNA-744/transforming growth factor β1 relationship regulates liver cirrhosis.

Authors:  Shuang Ren; Jiamei Chen; Qinglan Wang; Xuewei Li; Ying Xu; Xiao Zhang; Yongping Mu; Hua Zhang; Shuang Huang; Ping Liu
Journal:  Hepatol Int       Date:  2019-10-23       Impact factor: 6.047

3.  Expression profile and clinical significance of miRNAs at different stages of chronic hepatitis B virus infection.

Authors:  Tongjing Xing; Hongtao Xu; Wenqing Yu; Bian Wang; Jing Zhang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 4.  Advances of microRNAs in regulating mitochondrial function: new potential application in NAFLD treatment.

Authors:  Chuwei Yu; Jing Chen; Jin Ren
Journal:  Mol Biol Rep       Date:  2022-05-25       Impact factor: 2.742

Review 5.  MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma.

Authors:  Sirio Fiorino; Maria Letizia Bacchi-Reggiani; Michela Visani; Giorgia Acquaviva; Adele Fornelli; Michele Masetti; Andrea Tura; Fabio Grizzi; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Luca Di Tommaso; Arrigo Bondi; Sergio Sabbatani; Andrea Domanico; Carlo Fabbri; Paolo Leandri; Annalisa Pession; Elio Jovine; Dario de Biase
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

Review 6.  Complex interactions between microRNAs and hepatitis B/C viruses.

Authors:  Hong-Xia Fan; Hua Tang
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

7.  MicroRNA in dried blood spots from patients with Aagenaes syndrome and evaluation of pre-analytical and analytical factors.

Authors:  Monica Atneosen-Åsegg; Maria Melheim; Runar Almaas
Journal:  Pediatr Res       Date:  2020-09-15       Impact factor: 3.756

8.  Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2.

Authors:  Haoran Li; Burton B Yang
Journal:  Oncotarget       Date:  2012-12

9.  Progression from Excessive to Deficient Syndromes in Chronic Hepatitis B: A Dynamical Network Analysis of miRNA Array Data.

Authors:  Qi-Long Chen; Yi-Yu Lu; Gui-Biao Zhang; Ya-Nan Song; Qian-Mei Zhou; Hui Zhang; Wei Zhang; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-16       Impact factor: 2.629

10.  Circulating miR-583 and miR-663 Refer to ZHENG Differentiation in Chronic Hepatitis B.

Authors:  Hui Zhang; Yan Guan; Yi-Yu Lu; Yi-Yang Hu; Shuang Huang; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-10       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.